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It is firmly believed that the mechanism of action of SSRIs in major depression is
to inhibit the serotonin transporter, SERT, and increase extracellular concentration of
serotonin. However, this undisputed observation does not prove that SERT inhibition is
the mechanism, let alone the only mechanism, by which SSRI’s exert their therapeutic
effects. It has recently been demonstrated that 5-HT2B receptor stimulation is needed for
the antidepressant effect of fluoxetine in vivo. The ability of all five currently used SSRIs
to stimulate the 5-HT2B receptor equipotentially in cultured astrocytes has been known
for several years, and increasing evidence has shown the importance of astrocytes and
astrocyte-neuronal interactions for neuroplasticity and complex brain activity. This paper
reviews acute and chronic effects of 5-HT2B receptor stimulation in cultured astrocytes
and in astrocytes freshly isolated from brains of mice treated with fluoxetine for 14 days
together with effects of anti-depressant therapy on turnover of glutamate and GABA
and metabolism of glucose and glycogen. It is suggested that these events are causally
related to the mechanism of action of SSRIs and of interest for development of newer
antidepressant drugs.
Keywords: calcium homeostasis, fluoxetine signaling, 5-HT2 receptors, glucose metabolism, glutamate/GABA,
glycogen, major depression, PLA2
INTRODUCTION: SERT, THE 5-HT2B RECEPTOR AND SSRI
SSRI TARGETS
It is generally thought that the molecular mechanism of SSRIs
is the long-known blockage of serotonin (5-HT) reuptake by its
transporter SERT (Fuller and Wong, 1977; Wong and Bymaster,
1995). Binding of SSRIs to this transporter (Langer et al.,
1986; Launay et al., 2006; Diaz et al., 2012) leads to elevated
extracellular 5-HT levels, assumed to cause their antidepressant
effects. SSRIs do exert a direct inhibitory effect on the SERT
protein on the neuronal presynaptic plasma membrane (Zhou
et al., 2009). Recently the molecular basis for high-affinity
recognition of fluoxetine in the SERT molecule was unraveled
(Andersen et al., 2014). However, these findings do not prove
that SERT inhibition is the mechanism, let alone the only
mechanism, by which SSRI’s exert their therapeutic effects in
major depression.
Recently Diaz et al. (2012) demonstrated in intact brain
a raphe nuclei 5-HT2B receptor with relatively high affinity
for SSRIs, which was indispensable for the antidepressant effect
of fluoxetine. However, SSRI effects exerted via the 5-HT2B
receptor had previously been described not only in cultured
neurons (Launay et al., 2006) but also in cultured astrocytes
(Kong et al., 2002), where they have been thoroughly studied
(Li et al., 2008a, 2009; Zhang et al., 2010). The resultant induction
of signaling pathways in glia and neurons has been further
characterized in astrocytic and neuronal fractions from mice
treated for 2 weeks with fluoxetine. They may play a key role
in the antidepressant mechanism of SSRIs. Given the dominant
role ascribed to neurons in the mechanisms of SSRIs and other
psychiatric drugs it may appear surprising that studies found
the major chronic impact of SSRIs in the fluoxetine-treated
mice to be on astrocytes. However they are consistent with
the growing evidence for a major role of these cells in major
depression and its therapy studied in patients (Abdallah et al.,
2014a,b), postmortem brain (Rajkowska and Stockmeier, 2013)
or in models of this disease (Gosselin et al., 2009; Banasr et al.,
2010).
Astrocytes account for ∼25% of brain cortical volume and
are responsible for at least a corresponding fraction of oxidative
energy metabolism, mainly required for maintaining extracellular
glutamate, GABA, and K+ homeostasis, and synthesis of
glutamate and GABA via the glutamine-glutamate (GABA)
cycle (reviewed in Hertz, 2011). This cycle is well established
in the brain in vivo, where it represents the quantitatively
most important interaction between neurons and astrocytes. It
will be described in more detail below. Astrocytes synthesize
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all transmitter glutamate and GABA and accumulate most
after neuronal release. According to recent research (Duarte
and Gruetter, 2013), astrocytes account for an even larger
fraction of oxidative brain metabolism, when their role in
subsequent metabolism of released GABA before its partial
return via astrocytes to neurons also is taken into account.
These major roles of astrocytes are likely to be relevant for
antidepressant effects on glutamate homeostasis, excitatory and
inhibitory signaling, and glucose metabolism. Involvement of
the glutamine-glutamate (GABA) cycle remains to be studied
after SSRI administration, but it has been investigated in
patients suffering from major depression (Abdallah et al.,
2014a). Moreover, studies of the rapidly acting anti-depressant
drugs ketamine or riluzole (which have no known effect
on 5-HT2B receptors) have shown that increases in flux in
this cycle parallel recovery from experimental and clinical
depression (Chowdhury et al., 2008, 2012; Brennan et al.,
2010).
Besides discussing the 5-HT2B receptor as an SSRI target, this
review will deal with 5-HT2B receptors’ cellular locations; the
signaling pathways activated; short term effect on cell signaling;
and long-term-effects in cultured astrocytes and in fluoxetine-
treated animals. Consequences of long term (14 days) SSRI
treatment on gene up-regulation and editing in primary cultures
of astrocytes and in neurons and astrocytes freshly isolated from
the brains of mice treated with fluoxetine and/or in whole brains
from such animals are described in detail. Some of these effects
are exerted on genes mediating glutamate/glutamine transport
and interconversion and on glutamate and GABA receptor genes.
Other effects are exercised on genes which are not directly
related to glutamate signaling, but are important for the well-
established correlation between recovery from major depression
and increase in glucose metabolism in brain (Buchsbaum et al.,
1997; Mayberg et al., 2000; Kennedy et al., 2001). Finally, the
reviewed studies pinpoint acute and chronic effects on pathways
for glycogen turnover. This is important because glycogenolysis
is known to impact glutamate formation, learning and longer
term neuroplasticity (Gibbs et al., 2007, 2008; Duran et al., 2013).
Together, these changes may be the link between the molecular
and cellular changes due to 5-HT2B receptor binding and the
longer-term impact on depressive symptoms. Selective activation
of this receptor or intermediates of its downstream pathways
may accordingly constitute potential targets for pharmaceutical
development. Such development would be important, since (i) a
considerable fraction of patients suffering from major depression
do not respond adequately to current antidepressant therapy;
(ii) the response is slow except for a few recently tested drugs
(O’Leary et al., 2014); and (iii) even the relatively safe SSRIs can
have severe side effects if used in pregnant women (Ellfolk and
Malm, 2010) or after acute coronary occlusion (Rieckmann et al.,
2013).
THE CRITICAL IMPORTANCE OF THE 5-HT2B RECEPTOR FOR SSRI
EFFECTS
The 5-HT2B receptor was identified in 1987 (Cohen and
Fludzinski, 1987) and was thus unknown when SSRIs were
introduced and believed to lack relevant receptor effects. Like
other 5-HT2 receptors, the 5-HT2B receptor is Gq/11 protein-
coupled and stimulates phospholipase C (PLC) to generate
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) by
hydrolysis of phosphatidyl-inositol 4,5-bisphosphate (PIP2). This
triggers IP3 receptor-mediated increase of free cytosolic calcium
concentration ([Ca2+]i) (Deecher et al., 1993; Roth et al., 1998;
Porter et al., 1999) and additional second messenger effects.
During chronic exposure to fluoxetine these second messenger
effects may be responsible for the many reported changes
in gene expression, as well as alterations in metabolism and
the glutamine-glutamate (GABA) cycle that will be described
later.
The 5-HT2B receptor is expressed in mouse, rat, and human
brain (Kursar et al., 1994; Baez et al., 1995; Bonhaus et al.,
1995; Choi and Maroteaux, 1996). In astrocytes obtained
from mouse brain (Zhang et al., 2010) its mRNA expression
is ∼2 times higher than in neurons (Li et al., 2012, see
Figure 1). It is also a major 5-HT2 receptor in astrocyte
cultures (Kong et al., 2002). Neuronal expression has been
reported in Purkinje cells (Choi and Maroteaux, 1996) and
raphe nuclei (Diaz et al., 2012). Diaz et al. (2012) showed in
an in vivo rat model that 5-HT2B receptors are needed for
long-term behavioral effects of fluoxetine. These effects were
abolished in 5-HT−/−2B mice or after pharmacologic inactivation
of 5-HT2B receptors, whereas stimulation by a selective 5-HT2B
receptor agonist induced similar responses as fluoxetine in
behavioral assays. Fluoxetine-mediated neurogenesis (Manev
et al., 2003) was eliminated in 5-HT2B knock-out animals, and
acute fluoxetine administration to 5-HT−/−2B mice induced a much
smaller increase in hippocampal 5-HT levels than in wild type
mice.
ACUTE EFFECTS OF SSRIs ON 5-HT2B RECEPTORS AND
THEIR TARGETS
ACUTE EFFECTS ON 5-HT2B RECEPTORS ON NEURONS
5-HT2B receptor effects on SERT or inhibition of 5-HT release
has been shown in very young cultures of serotonergic neurons
and in neuronal-enriched cultures from the raphe nuclei (Azmitia
et al., 1990; Launay et al., 2006). However, these nuclei in addition
contain glia cells (Azmitia and Whitaker-Azmitia, 1991), which
may also be present in the cultures. Unfortunately our own
cultured neurons tolerate fluoxetine poorly. Moreover, they are
also young and the immature nervous system is different from
the mature brain (e.g., Hertz, 2013). However, future studies to
establish potential direct neuronal responses to fluoxetine would
be of high importance.
GLIAL 5-HT2B BINDING IS CRITICAL FOR IN VIVO EFFECTS OF SSRIs
Support for the concept that direct binding to 5-HT2B receptors
is important for SSRI’s mechanisms of action is that all presently
used SSRIs have virtually identical affinity for the 5-HT2B receptor
in cultured astrocytes (Zhang et al., 2010). This contrasts the huge
differences in their potency as inhibitors of 5-HT uptake (Wong
and Bymaster, 1995; Popik, 1999). Also inconsistent with SSRIs
owing their therapeutic effects solely to an action on SERT are
findings that substantial SERT occupancy (about 80%) occurs at
sub-therapeutic SSRI doses, and that increasing doses to clinically
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FIGURE 1 | Effect of fluoxetine on 5-HT2 receptor mRNA in astrocytes
and neurons obtained separately from both control mice (injected with
saline) and mice treated for 14 days with fluoxetine. mRNA expression
was measured by reverse transcription polymerase chain reaction (RT-PCR)
of 5-HT2A, 5-HT2B and 5-HT2C receptors in astrocytes and neurons isolated
by fluorescence-activated cell sorting (FACS) from cerebral hemispheres of
two different adult mice strains (FVB/NTg(GFAP-GFP)14Mes/J, providing
astrocyte-specific fluorescence, and B6.Cg-Tg(Thy1-YFPH)2Jrs/J, providing
neuron-specific fluorescence, although mainly of large glutamatergic
neurons). Results are shown for mice chronically treated with fluoxetine (10
mg/kg per day) and for untreated controls. They are means ± SEM of ratios
between scanned 5-HT2A, 5-HT2B or 5-HT2C receptor expression and
scanned expression of TATA-binding protein (TBP), used as housekeeping
gene. n = 3 (neurons) or 4 (astrocytes). *P > 0.05 vs. control group in
astrocytes (5-HT2B receptor) or in neurons (5-HT2C receptor). (Li et al., 2012).
effective levels causes only very minor increases in SERT binding
(Meyer et al., 2004). SERT-unrelated acute and chronic effects
of fluoxetine, including those by 5-HT2B receptor stimulation of
astrocytes may therefore be important for their mechanisms of
action.
ACUTE EFFECT OF FLUOXETINE ON 5-HT2B RECEPTORS AND THEIR
TARGETS IN CULTURED ASTROCYTES
Cultured astrocytes are well suited to acute and chronic studies
of SSRIs as they can survive undamaged in culture for a long
time. Effects on gene expression and editing can be compared
with those exerted in the brain in vivo after separation of an
astrocytic and a neuronal cell fraction as described by Lovatt et al.
(2007).
Fluoxetine displaces serotonin binding to cultured astrocytes
(Hertz et al., 1979). Kong et al. (2002) found expression of mRNA
expression of 5-HT2B and 5-HT2A receptors, but not of 5-HT2C
receptors in the cultures (Zhang et al., 1993). Lack of inhibition
by ketanserin showed that this was not a 5-HT2A receptor effect.
They also obtained quantitative data for displacement of the
universal 5-HT2 receptor ligand mesulergine by fluoxetine. Based
on these data the Ki value for fluoxetine’s displacement of 5-HT
was calculated to be 70 nM (Hertz et al., 2012). This affinity
is 4 times higher than that originally determined for binding
of fluoxetine in brain tissue to the 5-HT2C receptor, for which
fluoxetine initially was found to have the highest affinity (Wong
and Bymaster, 1995).
Studies on post receptor signaling in these glia cells
have shown effects on signaling targets such as growth
factors and glycogen synthesis. Both of these are known to
influence neuroplasticity, which is believed to be key factor
in the efficacy of SSRIs as antidepressants (Eom and Jope,
2009; Freitas et al., 2013). Acute administration of fluoxetine
increases [Ca2+]i and stimulates glycogenolysis (a [Ca2+]i-
dependent process) in cultured astrocytes (Zhang et al.,
1993; Chen et al., 1995). These effects are not limited to
cultured cells, since both fluoxetine and paroxetine support
learning in day-old chickens. This effect is inhibited by an
antagonist of the 5-HT2B,C receptor and by a glycogenolytic
inhibitor (Gibbs and Hertz, 2014). Further evidence that
the effects were specific to 5-HT2B binding as opposed to
SERT was that the same effects were obtained with almost
identical doses of SSRIs (Zhang et al., 2010) that affect 5-HT
uptake with widely different potency (Wong and Bymaster,
1995).
The signaling pathway activated by fluoxetine in cultured
astrocytes (Li et al., 2008a) is complex (Figure 2). Abolishment
of 5-HT2B receptor activity by its siRNA or administration of
the 5-HT2B receptor inhibitor SB204741 prevented any response,
further validating the concept that the 5-HT2B receptor is directly
stimulated. Phosphorylation of extracellular kinases 1 and 2
(ERK1/2) was established as an end point without examining
further downstream effects, except for a rapid increase in the
expression of the immediate early genes cfos and fosB. The
increase in [Ca2+]i (Chen et al., 1995) leads to activation of
metalloproteinases (MMPs) and shedding of growth factor(s),
perhaps mainly heparin-binding epidermal growth factor (HB-
EGF). This EGF receptor agonist is known to be present in adult
brain and to be required for synaptic plasticity (Oyagi et al.,
2011).
Growth factor release may link glial 5-HT2B binding to the
longer-term cellular and behavioral changes induced by SSRI
stimulation of receptor tyrosine kinases of the epidermal growth
factor (EGF) receptor (EGFR). Such an effect of G protein-
coupled receptors represents a transactivation process, a common
mechanism in astrocytes (Daub et al., 1997; Peavy et al., 2001;
Peng, 2004; Du et al., 2009). mRNA expression of the EGFR
is approximately 4 times higher in freshly isolated mouse brain
astrocytes than in corresponding neurons (Peng et al., 2014).
EGFR phosphorylation leads to activation of ERK1/2 and of
PI3K, with the latter causing AKT phosphorylation (Hertz
et al., 2012; Peng et al., 2014). Moreover, released growth factor
also acts on neurons (Li et al., 2008b) and may be at least
one of the stimuli for the well known fluoxetine-stimulated
neurogenesis (Manev et al., 2003) and effects on synaptic
activity (Oyagi et al., 2011). Within 1 h the phosphorylation of
ERK1/2 induces gene expression of cfos and fosB in astrocytes
(Li et al., 2008a), shown in Figure 3 to be abolished by inhibitors
of the pathway indicated in Figure 2. Fluoxetine also rapidly
induces ERK1/2-dependent enhancement of gene expression of
glial-derived nerve factor (GDNF) in the cultured astrocytes used
by Mercier et al. (2004). These cultures differ in several respects
from ours, e.g., by being prepared from rats instead of mice and
without exposing the cells to the differentiating agent dibutyryl
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FIGURE 2 | Schematic illustration of pathways leading to stimulation
of extracellular-regulated kinase (ERK) and AKT phosphorylation by
fluoxetine in astrocytes. Fluoxetine binds to 5-HT2B receptors. The
activation of the receptors induces protein kinase C (PKC) activity and
increase of intracellular Ca2+ concentration ([Ca2+]i) by Ca2+ release from
intracellular stores. The latter activates Zn-dependent metalloproteinases
(MMPs) and leads to shedding of growth factor(s). The released epidermal
growth factor receptor (EGFR) ligand stimulates phosphorylation of the
EGFR. The downstream target of EGFR, ERK (shown in blue) is
phosphorylated via the Ras/Raf/MEK pathway, and AKT is phosphorylated
via PI3K pathway. PIK3 is also known to catalyze the formation of PIP3 from
PIP2. During fluoxetine administration, phosphorylation of ERK and AKT was
prevented after siRNA administration against the 5-HT2B receptor or after
administration of inhibitors (shown in yellow) of this receptor (SB204741), of
PKC (GF 109293X), of intracellular Ca2+ homeostasis (BAPTA/AM, an
intracellular Ca2+ chelator), of Zn-dependent MMPs (GM6001), of the
receptor-tyrosine kinase of the EGFR (AG1478), of ERK phosphorylation
(U0126, a mitogen-activated kinase (MEK) inhibitor) or of the AKT pathway
(LY294002, a PI3K inhibitor). This inhibition is an indication of participation of
all the inhibited factors in the normal signaling pathway. (Hertz et al., 2012).
cyclic AMP. It is re-assuring that several aspects of fluoxetine
effects are the same. However, some differences were also found,
which is not unexpected when cultured cells are used.
A further important step where glial 5-HT2B receptor
binding may influence the longer-term cellular and behavioral
effects of SSRIs is the impact on glycogen synthesis. Glycogen
turnover, i.e., interspersed glycogen synthesis and glycogenolysis,
is indispensable during learning (Gibbs and Hutchinson,
2012; Hertz et al., 2013a). The acute memory-enhancing,
glycogenolysis-dependent effect of both fluoxetine and paroxetine
has been mentioned (Gibbs and Hertz, 2014). Knock-out of
brain glycogen synthase abolishes learning of new motor and
cognitive skills (Duran et al., 2013). It is likely that fluoxetine also
affects glycogen synthesis, since the AKT pathway (Figure 2) is
stimulated, as shown by AKT phosphorylation in the cultured
cells (Hertz et al., 2012; Peng et al., 2014). Phosphorylated
AKT in turn inhibits glycogen synthase kinase-3β (GSK-3β) by
phosphorylation (Fang et al., 2005). This probably stimulates
FIGURE 3 | Activation of EGF receptors and of ERK is required for
up-regulation of mRNA expression of c-fos and fosB by fluoxetine in
astrocytes. Cells were incubated for 60 min in serum-free medium in the
absence of any drug (Control) or in the presence of 10 µM fluoxetine alone
or together with 1 µM AG 1478 or 10 µM U0126. Average mRNA
expression (n = 3) was quantitated as ratios between c-fos and TBP, used
as a house-keeping gene (A) and between fosB and TBP (B). SEM values
are indicated by vertical bars. *Indicates statistically significant (P < 0.05)
difference from Control, AG 1478, fluoxetine plus AG 1478, U0126, and
fluoxetine plus U0126 groups for c-fos and fosB. (Li et al., 2008a).
glycogen synthesis, since activation of glycogen synthase by
GSK-3 decreases its activity (Embi et al., 1980; De Sarno et al.,
2002).
Consistent with these findings in cultured astrocytes Plenge
(1976) found an acute increase in brain glycogen after
administration of Li+ (“lithium”), a known inhibitor of GSK3.
As shown in Figure 4, this reflected increased glycogen synthesis
(Plenge, 1982). Effects of fluoxetine (and of electroconvulsive
therapy) by inhibitory phosphorylation of GSK-3 have also been
summarized by Gould et al. (2006), and the role of GSK-3 in
synaptic plasticity, including memory, discussed by Bradley et al.
(2012).
The Jope group found in whole brain that 5-HT2B stimulation
or acute fluoxetine administration decreases the levels of
phosphorylated GSK3 (Li et al., 2004; Polter et al., 2012). This
response was blunted or absent in young mice (Beurel et al.,
2012), consistent with astrocytic localization since astrocytes
are mainly generated postnatally (Schousboe, 1971; Ge et al.,
2012). Other papers from this group showed that deficiency
in inhibitory phosphorylation of GSK-3 increases sensitivity
to mood disturbances (Polter et al., 2010) and that GSK-3 is
required for the antidepressant effect of ketamine (Beurel et al.,
2011).
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FIGURE 4 | Stimulation of glycogen synthesis by inhibition of GSK3.
Specific activity of brain glycogen was measured relatively to the specific
activity of blood glucose in lithium-treated rats. At 4–12 min after injection
of radioactive glucose, 15 µmol LiCl was intracisternally injected into the
rats. The brains were frozen 2 h after the injection and incorporation of
radioactivity into glycogen determined. *P < 0.05 (4–8 rats at each point).
(Plenge, 1976).
FURTHER INTERACTIONS BETWEEN ASTROCYTES AND
NEURONS REQUIRED FOR NORMAL FUNCTION IN ADULT
BRAIN
ASTROCYTES RECEIVE TRANSMITTER SIGNALS FROM NEURONS AND
RELEASE “GLIOTRANSMITTERS” AND OTHER NEUROACTIVE
COMPOUNDS
The response of astrocytes to the SSRI 5-HT2B agonists is
only one example of how astrocyte neurotransmitter receptors
may modulate synaptic strength and plasticity. An increasing
number of studies have demonstrated that astrocytes express
receptors for most neurotransmitters and release neuroactive
substances that modulate neuronal activity (Ben Achour and
Pascual, 2010). Besides the already mentioned growth factor
release in response to stimulation by 5-HT2B receptors (and many
other neurotransmitter receptors) they release compounds like
adenosine triphosphate (ATP) and glutamate as gliotransmitters.
The amount of glutamate released is much smaller than
that released from glutamatergic neurons, but it is of special
importance because it acts on glutamate receptors which
are not located postsynaptically. In this manner astrocytes
contribute to regulation of long-term potentiation (LTP), long-
term depression (LTD) and neuroplasticity (Ben Achour and
Pascual, 2010).
ASTROCYTES SYNTHESIZE ALL TRANSMITTER GLUTAMATE AND GABA
AND ACCUMULATE MOST AFTER NEURONAL RELEASE
Neurons cannot carry out glutamate synthesis from glucose
because they lack an enzyme (pyruvate carboxylase), which is
critical for glutamate synthesis in vivo (Shank et al., 1985) and
in culture (Yu et al., 1983). The majority of glutamate released
as a neurotransmitter is taken up by glial cells. Subsequently
glutamate is transferred to neurons in the glutamine-glutamate
(GABA) cycle via astrocytic glutamine formation, release of
glutamine, and its uptake in neurons, where it is deamidated
to glutamate (Hertz and Zielke, 2004; Schousboe et al., 2013).
In glutamatergic neurons glutamate is used as a transmitter,
and in GABAergic neurons it is converted to GABA (Figure 5).
In gray matter (Lebon et al., 2002) of the awake human
brain the rate of this process equals about 75% of the rate of
total glucose consumption, and in the deeply anesthetized, iso-
electric brain it is abolished (Sibson et al., 1998; Hyder and
Rothman, 2012; Duarte and Gruetter, 2013). The correlation
between cycle flux and brain glucose utilization is linear (Sibson
et al., 1998; Hyder and Rothman, 2012). Key processes in this
massive astrocyte-neuronal interaction are strictly regulated
and/or complex. This applies to astrocytic release of glutamine
(Nissen-Meyer and Chaudhry, 2013) and neuronal formation
of glutamate from glutamine (Palaiologos et al., 1989), which
requires concomitant stimulation of glycolysis (Chowdhury
et al., 2014; Verkhratsky et al., 2014). This requirement explains
part of the linear correlation between glucose utilization and
the glutamine-glutamate (GABA) cycle. The cycle also brings
previously released transmitter amino acids back to neurons after
an initial uptake in astrocytes (Figure 5). This is associated with
a small amount of energy expenditure (for glutamate uptake
and glutamine formation). Return to astrocytes of previously
released transmitter and its transport back to neurons represents
the major part of the flux in the glutamine-glutamate (GABA)
cycle. Only 15–25% of the flux serves to transfer newly synthesized
glutamate from astrocytes to neurons (an anaplerotic process)
and return glutamate to astrocytes for oxidative degradation (a
cataplerotic process). The anaplerotic de novo synthesis requires
glucose utilization in astrocytes (one glucose molecule for each
molecule of glutamate). Cycle flux is also significantly correlated
with glutamate content in human brain (Abdallah et al., 2014a).
Since the glutamate content in astrocytes is very low (Lebon et al.,
2002), this mainly represents neuronal glutamate.
The GABA component of the glutamine-glutamate (GABA)
cycle accounts for ∼20% of cycle flux from neurons to astrocytes
(Patel et al., 2005; Duarte and Gruetter, 2013). GABA synthesis
and metabolism to glutamine shows similarities and differences
from production and degradation of glutamate. In contrast to
direct astrocytic uptake of most neuronally released glutamate,
astrocytically accumulated GABA must first be converted to
glutamate in the TCA cycle as described below. This requires
condensation of oxaloacetate (OAA) with acetyl Coenzyme A
(ac.CoA; Figure 5) but no pyruvate carboxylation (Patel et al.,
2005; Duarte and Gruetter, 2013; Lanz et al., 2013). The generated
glutamate might be directly converted to GABA. Cultured
GABAergic neurons show also a substantial uptake and re-
utilization of released GABA (Schousboe et al., 2013). Both of
these mechanisms may make GABA synthesis less dependent
upon the classical glutamate-glutamine (GABA) cycle. However
a recent in vivo study in which neuronal reuptake was inhibited
showed minimal impact on the fraction of GABA synthesis from
glutamine suggesting that direct reuptake may be significantly
lower at least in the cerebral cortex (Patel et al., 2015). Further
studies will be needed to fully understand the regional and
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FIGURE 5 | Cartoon of glucose metabolism via pyruvate in neurons
(left—N) and astrocytes (right—A) and of glutamine–glutamate
(GABA) cycling. In both cell types 2 molecules pyruvate are formed from
one molecule glucose by glycolysis. Their metabolism via acetyl Coenzyme
A (ac.CoA) leads to formation of citrate by condensation with pre-existing
oxaloacetate (OAA) in the tricarboxylic acid (TCA), an end-result of the
previous turn of the cycle. Citrate oxidation in the TCA cycle includes two
decarboxylations, leading to re-formation of OAA, ready for another turn of
the cycle, and to production of large amounts of energy (ATP). Pyruvate
carboxylation occurs only in astrocytes. It creates a new molecule of OAA,
which after condensation with ac.CoA, derived from a second molecule of
pyruvate, forms a new molecule of citrate. This process can be used for
replacement of worn TCA cycle intermediates. More important in the
present context is that α-ketoglutarate (α-KG), one of the intermediates of
the TCA cycle can leave the cycle to form glutamate (glu), catalyzed by
aspartate aminotransferase and/or glutamate dehydrogenase. In turn,
glutamate is amidated to glutamine (gln), catalyzed by the cytosolic and
astrocyte-specific enzyme glutamine synthetase. The arrows between
neuronal α-KG and glu do not indicate net synthesis but only isotope
exchange. After release from astrocytes glutamine is accumulated in
glutamatergic and GABAergic neurons (lower line of the
glutamine–glutamate(GABA) cycle [Glu–gln cycle]), converted to glutamate
(and in GABAergic cells onward to GABA) and released as transmitter.
Released glutamate is almost quantitatively re-accumulated in the
astrocytic cytosol. Part of the released GABA is also accumulated in
astrocytes [upper line of the glutamine–glutamate (GABA) cycle], but its
conversion to glutamate requires oxidative metabolism in astrocytes as
described in the text. Here, 75–85% of accumulated glutamate is converted
to glutamine and re-enters the glutamine–glutamate (GABA) cycle. The
remaining 15–25% is oxidatively degraded after re-conversion via
α-ketoglutarate to malate, exit of malate to the cytosol, decarboxylation to
pyruvate by cytosolic malic enzyme and further pyruvate oxidation in the
TCA cycle via ac.CoA. This part must in the long term be replaced by a
quantitatively similar de novo production of glutamate from glucose as
described above. Alternatively, malate may not exit the mitochondria but
after formation of OAA and condensation with ac.CoA be used for
re-synthesis of another molecule of glutamate. Under some conditions de
novo synthesis of glutamate exceeds its oxidation, leading to an increase in
tissue glutamate (e.g., Gibbs et al., 2007; Mangia et al., 2012). Moreover
the 15–25% of total flux in the glutamine-glutamate (GABA) cycle, which is
resynthesized and oxidized might change, if the equilibrium is disturbed
between the activities of enzymes catalyzing the interconversion between
glutamate and α-ketoglutarate (aspartate aminotransferase and/or
glutamate dehydrogenase) and that catalyzing glutamate conversion to
glutamine (glutamine synthetase). This could potentially also happen if the
concentrations of the reactants are altered, e.g., as a result of a change in
pyruvate carboxylase activity. There is no proof of such effects,
(Continued )
FIGURE 5 | Continued
but they can also not be excluded. Neuronal re-supply of GABA may be less
dependent on the glutamate-glutamine (GABA) cycle than their supply of
glutamate, as discussed in the text. (Hertz et al., 2013b).
activity dependance of direct neuronal reuptake vs. astrocyte
uptake.
The conversion of GABA to glutamate is a complex process, in
which GABA initially enters the astrocytic mitochondria, possibly
in exchange with glutamate allowing exit of newly synthesized
glutamate to the cytosol. It is then transaminated to succinic
semialdehyde and oxidized to succinate, which enters the TCA
cycle and via oxaloacetate (OAA) and citrate is converted to α-
ketoglutarate, from which glutamate is generated by the same
transamination that catalyzes the conversion of GABA to succinic
semialdehyde. The participation of TCA cycle activity means
that complete oxidation also could have occurred after exit of
malate (Figure 5). However, Duarte and Gruetter (2013) found
no increase in pyruvate carboxylation from previously reported
values, indicating no major increase in anaplerosis/cataplerosis,
compared to cycling related to glutamatergic signaling.
In the long term, rates of anaplerosis and cataplerosis must
be identical (Lebon et al., 2002; Sonnewald, 2014), but this
is not necessarly so in the short term, since brain glutamate
content can transiently increase. This happens during specific
phases of learning (Gibbs et al., 2007), although children with
reading difficulties (Pugh et al., 2014) or with ADHD (Carrey
et al., 2007) have an increased brain glutamate content. The
latter findings might be related to hyperexcitability. In cases of
epileptic seizure and even physiological visual stimulation there
is an acute increase in brain glutamate (Peca et al., 2010; Mangia
et al., 2012). The larger involvement of astrocytic metabolism
during anaplerosis/cataplerosis provides increased possibilities
for astrocytic regulation of the cycle. Nevertheless even
simple astrocytic involvement in return of previously released
transmitter provides a possibility for astrocytic regulation,
because glutamine can traverse the astrocytic syncytium (Cruz
et al., 2007). It cannot even be excluded that incoming glutamate
from neuronal release might be re-directed to GABA-ergic
neurons and vice-versa.
K+ HOMEOSTASIS
There is increasing evidence that increased extracellular K+
resulting from neuronal excitation is initially accumulated
in astrocytes by the astrocytic Na+, K+-ATPase, which in
contrast to the neuronal enzyme is stimulated by above-normal
extracellular K+ concentrations (reviewed by Hertz et al., 2014b).
It is subsequently released via Kir4.1 channels, probably after
transport through the astrocytic syncytium, distributing the
amount released over a larger area and thus preventing excessive
local extracellular K+ increase. This allows secondary uptake
by the neuronal Na+, K+-ATPase, preventing neuronal K+
depletion. This process is strikingly reminiscent of how astrocytes
handle released neuronal glutamate. However in neither case is it
known which advantages the energetically costly double uptake
provides for the brain.
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CHRONIC EFFECTS OF FLUOXETINE
OBJECTIVES AND METHODOLOGIES
The several weeks delay between SSRI administration and
improvement in depressive symptoms show that chronic effects
are the most clinically relevant (Nierenberg et al., 2000). The
long life span of astrocyte cultures allows chronic studies of
both functional properties and gene expression and editing.
In the studies described below all effects on gene expression
were confirmed in isolated neuronal and astrocytic cell fractions
(Lovatt et al., 2007) prepared from chronically fluoxetine-treated
animals as described in the legend of Figure 1. Our own
observations using these methodologies will be supplemented
with information from studies by other authors, which provide
no information about cellular location(s). While the absence of
SERT in cultured astrocytes excludes that the gene effects could
be secondary to SERT inhibition, those shown in neurons in intact
animals could be SERT-related.
The effects of SSRIs on gene expression and editing in both
neurons and astrocytes from fluoxetine-treated animals (10 mg
fluoxetine hydrochloride/kg per day for 14 days).are summarized
in Table 1. The expression and editing changes in both neurons
and astrocytes are present in whole brain as also shown in
the Table. Many of the genes studied are relevant for major
depression. This includes a key role for glutamate in major
depression and its treatment (Barbon et al., 2006; Sanacora et al.,
2007, 2012; Chowdhury et al., 2008, 2012; Banasr et al., 2010;
Hertz et al., 2012; Li et al., 2012; Sanacora and Banasr, 2013; Niciu
et al., 2014). Furthemore some oppositely-directed gene changes
have been shown in an animal model of depression, indicating their
therapeutic relevance (Li et al., 2012; Peng et al., 2014).
EFFECTS ON GLUTAMATE, GABA AND ENERGY METABOLISM
Patients suffering from major depression show evidence of
increased glutamatergic activity (Mitani et al., 2006; Hashimoto
et al., 2007; Kanner, 2014) and decreased GABA-ergic activity
(Bajbouj et al., 2006; Kanner, 2014) as well as of cortical
GABA levels (Sanacora et al., 2004). Successful therapy of major
depression lowers cortical glutamate in brain (Abdallah et al.,
2014a) and raises GABA (Sanacora et al., 2002; Bhagwagar et al.,
2004).
Glutamine synthetase is down-regulated in brains from
depressed patients (Rajkowska and Stockmeier, 2013). This
is consistent with the increased amino acid neurotransmitter
(glutamate and GABA) cycling between astrocytes and neurons
after antidepressant treatment with ketamine or riluzole
(Chowdhury et al., 2008, 2012), Moreover, inhibition of
glutamine synthetase or of the transporter mediating glutamine
uptake into neurons causes depression-like symptoms in animal
models (Lee et al., 2013).
In a recent 13C MRS study no significant difference in cycling
flux, determined from glutamate and glutamine 13C labeling
from [1-13C]glucose, (0.19 ± 0.05 (SD) vs. 0.18 ± 0.04 (SD)
µmol/g per min) was found between healthy and depressed
individuals (Abdallah et al., 2014a). The rate of GABA synthesis
was also unaltered. However, inhibition of glutamine synthase
or glutamate uptake does not necessarily decrease glutamate
flux to glutamine. The flux can still be maintained if glutamate
release is not inhibited but at the cost of higher extracellular
and glial glutamate levels, as has been seen when glial glutamate
uptake or glutamine synthase is inhibited in animal models
(Rothstein et al., 1996; Eid et al., 2012). The elevated glutamate
would be expected to alter synaptic function. Furthermore it
could lead to a change in the ratio of released glutamate that is
oxidized in astrocytes vs. glutamate that is directly converted to
glutamine.
In patients suffering from depression, brain glucose
metabolism is reduced (Little et al., 1996, 2005; Videbech,
2000; Rasgon et al., 2008; Abdallah et al., 2014a) in parallel with
the severity of the illness (Kimbrell et al., 2002). Normalization
occurs following SSRI treatment (Buchsbaum et al., 1997;
Mayberg et al., 2000; Kennedy et al., 2001). Anti-depressant doses
of ketamine increase oxidative metabolism in neuronal and glial
cells in the brain in vivo (Chowdhury et al., 2012). Consistent
with this therapeutic effect Abdallah et al. (2014a) found a
large (one quarter) decrease in the rate of glucose oxidation by
glutamatergic neurons in depressed patients.
On account of the linear relationship between neuronal
activity and neuronal oxidative demand beyond isoelectricity,
the metabolic decrease in glutamatergic neurons suggests a
drastic reduction of neuronal activity. An increased cycling
after treatment with riluzole or ketamine might remedy this
deficiency regardless whether or not decreased glutamate cycling
is a key component of the pathophysiology of major depression.
Increased energy metabolism in glutamatergic neurons is required
not only for release of neurotransmitter but probably even more
for effects exerted via their glutamate receptors.
In conclusion, in spite of convincing evidence for alterations
in glutamine-glutamate (GABA) fluxes and associated energetics
in animal models of major depression and its treatment there
are still unanswered questions in human depression. This is
perhaps partly because the cycle is of key importance for both
glutamatergic and GABAergic signaling, and partly because
there are many different glutamate receptors. Effects of chronic
fluoxetine treatment of mice on glutamate and GABA receptors
in whole brain, astrocytes and or neurons might provide further
clues.
GLUTAMATE AND GABA RECEPTOR AND TRANSPORTER GENES
Fluoxetine effects on up-regulation and/or editing of genes of
several glutamate receptors are shown in Table 1. Receptor up-
regulation might potentially correct the abnormal ratio between
energetics and the glutamine-glutamate (GABA) cycle observed
by Abdallah et al. (2014a), whereas the effects of editing may vary
between receptors and editing sites. Editing requires ADARs, a
family of adenosine deaminases, which catalyze deamination of
adenosine to inosine in mRNAs. This changes the amino acids in
the translated protein sequence, since inosine is read as guanosine
(Bass, 2002). ADAR 2 is upregulated in astrocytes but not in
neurons in mice treated with fluoxetine (Table 1). GluK2 is up-
regulated and edited in astrocytes at all its 3 editing sites (Li
et al., 2011a, 2012), and GluK4 is upregulated in neurons (Li
et al., 2012). The Gluk2 editing may be the reason why a normal
increase in [Ca2+]i in cultured astrocytes in response to 100 µM
glutamate is abolished by fluoxetine treatment (Li et al., 2011a).
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The human GluK2c splice variant in brain is mainly expressed
in non-neuronal cells (Barbon et al., 2008). Mice with GluK2
receptor knock-out, exhibit less anxious or more risk-taking type
behavior and less manifestation of despair (Shaltiel et al., 2008).
Obsessive-compulsive disorder (OCD) is genetically linked to
abnormalities in the GluK2 gene, Grik2 (Delorme et al., 2004;
Sampaio et al., 2011). The neuronal up-regulation of GluK4
by fluoxetine may appear paradoxical since genetic ablation of
this receptor subunit causes anxiolytic and antidepressant-like
behavior in mice (Catches et al., 2012). However, there is a risk
of elevated suicidality during initiation of antidepressant therapy
(Fava and Rosenbaum, 1991; Kraus et al., 2010; Trivedi et al.,
2011; Singh et al., 2013), which might be related to this up-
regulation.
The GluA2 gene is expressed in both neurons and astrocytes
(Cahoy et al., 2008), and it is up-regulated in whole brain by
fluoxetine treatment (Ampuero et al., 2010; Vialou et al., 2010;
Barbon et al., 2011). Up-regulation in neuronal dendrites leads
to structural plasticity (Rubio et al., 2013). Mice susceptible
to chronic social defeat show a significant decrease in GluA2
levels, while resilient mice showed increased GluA2 levels (Vialou
et al., 2010). GluA1 (Barbon et al., 2006; Ampuero et al.,
2010) and GluA4 (Barbon et al., 2011) are also upregulated in
brains of fluoxetine-treated animals, but GluA3 is less affected
(Barbon et al., 2006). In contrast to the lack of fluoxetine effect
on mGlu5 in both astrocytes and neurons (Table 1) and of
an unaltered mGluR2 and mGluR3 expression in whole brain
in major depression (Muguruza et al., 2014), mGluR7 is up-
regulated in whole brain after fluoxetine treatment (Ampuero
et al., 2010; O’Connor et al., 2013). Very little information is
available about possible fluoxetine effect on NMDA receptors.
The GABA-synthesizing enzyme glutamic acid decarboxylase
(GAD) is upregulated in hippocampus but not in prefontal
cortex by 2 weeks of fluoxetine treatment (Guirado et al., 2012).
A hippocampal up-regulation of the GABAB receptor has also
been reported (Sands et al., 2004). A decrease in cerebrospinal
fluid of patients with depression of the neurosteroid 3α-hydroxy
5α-pregnan-20-one (allopregnanolone), which enhances GABA
action at GABAA receptors, is corrected by fluoxetine treatment
(Pinna et al., 2009). The likely reason for this is that fluoxetine,
sertraline, and paroxetine acutely cause a large decrease of the Km
for conversion of 5α-dihydroprogesterone to allopregnanolone
by human 3α-HSD type III (Griffin and Mellon, 1999). In turn,
5α-dihydroprogesterone is formed from progesterone (and some
other substrates) by the rate-limiting enzyme 5α-reductase. In
cerebellum this enzyme is mainly expressed in astrocytes and
oligodendrocytes (Kiyokage et al., 2014). However, in frontal
cortex, where allopregnanolone is down-regulated in depressed
patients, it was reported to be synthesized in glutamatergic
neurons (Agis-Balboa et al., 2014). A decrease of corticolimbic
allopregnanolone content induced in mice by social isolation
as well as the induced behavioral changes are sterospecifically
normalized by fluoxetine by a mechanism independent from 5-
HT reuptake inhibition (Pinna et al., 2009). Thus, fluoxetine
facilitates GABAA receptor neurotransmission and effectively
ameliorates depression by stimulating brain steroidogenesis in a
SERT-independent manner.
PHOSPHOLIPASE GENES
A polymorphism in the calcium-dependent phospholipase 2
(cPLA2) gene is connected with increased risk for major
depression (Pae et al., 2004). This enzyme is strongly expressed
in astrocytes (Lautens et al., 1998; Balboa and Balsinde, 2002; Sun
et al., 2004). In cultured astrocytes cPLA2 causes transactivation
of the EGF receptor and ERK1/2 phosphorylation (Xia and
Zhu, 2011). Its activation releases the unsaturated fatty acid
arachidonic acid from membrane-bound phospholipids (Felder
et al., 1990; Qu et al., 2003; Rapoport, 2008). In agreement with
an up-regulation reported in whole brain (Rapoport, 2008), Li
et al. (2009) showed a slow and selective up-regulation of mRNA
and protein expression of cPLA2a, the major cPLA2 isoform,
in cultured mouse astrocytes during chronic incubation with
fluoxetine (Table 1). The up-regulation was abrogated by the
5-HT2B antagonist SB 204741, and by inhibitors of the fluoxetine
signaling pathway shown in Figure 2. Up-regulation, specifically
of cPLA2a was confirmed in freshly dissociated mouse astrocytes
after 2 weeks fluoxetine treatment, whereas no effect was found in
neurons (Li et al., 2012).
sPLA2 is upregulated by fluoxetine in neurons and whole
brain, but not in astrocytes (Table 1). Some subtypes of
sPLA2 also stimulate arachidonic acid release (Murakami
et al., 1998). Exogenously applied sPLA2 causes an increase in
neurotransmitter release from cultured hippocampal neurons
(Wei et al., 2003).
One of the many effects of arachidonic acid is to stimulate
glucose metabolism in cultured astrocytes (Yu et al., 1993). So does
treatment with 10 µM fluoxetine for 24 h (Allaman et al., 2011),
which might have sufficed to induce an increase in cPLA2, whereas
acute exposure to fluoxetine has no corresponding effect (L. Peng
and L. Hertz, unpublished experiments). Stimulation of glucose
metabolism by arachidonic acid in vivo (Sublette et al., 2009) may
be important in the treatment of depressive illness, as shown in
Figure 6. Arachidonic acid in addition stimulates glycogenolysis
(Sorg et al., 1995; Hertz et al., 2015) and seems to enhance
signaling via glutamatergic receptors of the AMPA and mGluR
subtypes (Schaeffer and Gattaz, 2008).
Brain glycogenolysis is activated by a multitude of transmitters
(Xu et al., 2014; Hertz et al., 2015), Increased glycogenolysis has
been found in paroxetine-treated mice (Webhofer et al., 2013)
and in astrocyte cultures treated with 10 µM fluoxetine for
more than 1 week, whereas shorter treatment led to a decrease
(Kong et al., 2002). Astrocytic glutamate production depends on
glycogenolysis (Gibbs et al., 2007). However, glycogenolysis has
additional wide-reaching effects on neuroplastic changes, which
are likely to be associated with chronic actions of SSRIs. Thus,
Duran et al. (2013) found an absence of appropriate postsynaptic
LTP responses to high-frequency stimulation in alert, behaving
mice with a specific knock-out of brain glycogen synthase.
The acute effect of fluoxetine on GSK-3 via PI3K/AKT and
the demonstration that the GSK-3 inhibitor lithium stimulates
glycogen synthesis (Plenge, 1982) suggest that potential chronic
effects of fluoxetine on glycogen formation might be very important
for its mechanism of action. This conclusion is consistent with
the suggestion by Li and Jope (2010) that GSK-3 is a central
modulator of mood regulation. Recent studies by Gu and
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FIGURE 6 | Correlation between cerebral metabolic rate of glucose
metabolism and plasma arachidonic acid levels. Correlation between
arachidonic acid as a percentage of total phospholipid polyunsaturated
essential fatty acids and glucose utilization (rCMRglu) measured by
fluoro-deoxyglucose PET scan in an area of right temporoparietal cortex that
included precentral gyrus, superior temporal gyrus, and inferior parietal
lobule in medication-free patients. (Sublette et al., 2009).
Peng showed a tripling of astrocytic glycogen content after 14
days of treatment with 1 µM fluoxetine, but a caveat is that
with this concentration of fluoxetine the transient decrease in
glycogenolysis described above (Kong et al., 2002) may not have
subsided after 2 weeks. However, the findings by Plenge (1982) of
acute effects of lithium strongly suggest that the stimulation of the
PI3K/AKT pathway by chronic treatment with 10 µM fluoxetine
does stimulate glycogen synthesis, and treatment of cultured
astrocytes with 10 µM fluoxetine treatment for 14 days increased
fluoxetine-induced AKT phosphorylation (Hertz et al., 2012).
In contrast, chronic lithium treatment abolishes the increased
incorporation of glucose into glycogen seen after acute exposure
to lithium (Plenge, 1982). The importance of SSRI-induced effects
on glycogen is consistent with its crucial involvement in astrocytic
signaling (Gibbs et al., 2007; Obel et al., 2012; Hertz et al., 2013a,
2014b; Mangia et al., 2013; Xu et al., 2013; Webhofer et al., 2013).
THE CALCIUM CHANNEL GENE CAv1.2
[Ca2+]i is low in resting cells (∼100 nM, compared to 1–
2 mM in the extracellular fluid). Increases in [Ca2+]i are an
essential component of virtually all astrocytic activities (e.g.,
formation of glutamate, glycogenolysis, and effects of many
transmitters) (Gibbs et al., 2007; Hertz et al., 2015). [Ca2+]i
increase is also required for transmitter-induced stimulation of
several TCA-cycle enzymes and glutaminase (Halestrap, 1989;
Denton and McCormack, 1990; Rutter et al., 1996) and for a
direct stimulation of oxidative phosphorylation (Gaspers and
Thomas, 2008) in many cell types. Such enzyme stimulations
have been demonstrated in cultured astrocytes (Subbarao and
Hertz, 1991; Huang and Hertz, 1995; Huang et al., 2000; Hertz
et al., 2010). Ca2+ transport across the cell membrane is therefore
of great importance for astrocytic functions. One route of
entry is via L-channels opened by membrane depolarization
(Li et al., 2011b; Du et al., 2014). The evoked [Ca2+]i rise
is increased after chronic treatment with fluoxetine, because
of up-regulation of the L-channel gene Cav1.2 (Du et al.,
2014), shown both in cultured cells and in astrocytes freshly
obtained from fluoxetine-treated mice. It is not up-regulated
in neurons (Table 1). The fluoxetine-induced up-regulation
counteracts a down-regulation of capacitative Ca2+ uptake
via store-operated channels (Socs), found in astrocytes after
treatment with fluoxetine (Li et al., 2011b). The antibipolar drug
carbamazepine has a similar effect on Socs in both astrocytes
(Yan et al., 2013) and neurons (unpublished), but it has no
effect on Cav1.2. A similar neuronal down-regulation of Socs by
fluoxetine would be advantageous by reducing the ability of stress-
released neuropeptide corticotropin-releasing hormone (CRH)
to decrease dendritic spine density in an NMDA- and Ca2+-
dependent process (Andres et al., 2013). SSRI effects on [Ca2+]i is
not limited to cultured cells, since citalopram or fluoxetine acutely
induces astrocytic [Ca2+]i increase in mouse brain slices (Schipke
et al., 2011).
5-HT RECEPTORS GENES AND SERT
Fluoxetine interactions with 5-HT receptors are age-dependent
(Sarkar et al., 2014) and only effects on adult individuals will
be discussed. In contrast to the 5-HT2B receptor’s up-regulation
by 14 days of in vivo treatment with fluoxetine, the astrocytic
5-HT2A and 5-HT2C receptors are unaltered (Table 1). After
2 weeks fluoxetine treatment all editing sites in the 5-HT2B
receptor become edited in astrocytes (Li et al., 2012). In cultured
astrocytes up-regulation of the 5-HT2B receptor occurs slowly
(Hertz et al., 2014a). Editing of the receptor is faster and abolishes
the 5-HT-induced increase in IP3 turnover. This together with a
similar up-regulation and editing of 5-HT2C receptors in neurons
(Table 1) are consistent with an early suggestion that chronic SSRI
treatment reduces 5-HT2C/5-HT2B receptor responsivity in rats
(Lightowler et al., 1994).
In whole brain fluoxetine-induced editing of the HT2C
receptor has repeatedly been described (Niswender et al., 2001;
Gurevich et al., 2002; Englander et al., 2005). It requires PKC
and ADAR activity (Schmauss et al., 2010). The fluoxetine-
induced changes in editing are opposite to those seen in suicide
victims (Gurevich et al., 2002). These findings might suggest that
a reduced agonist activity after editing (see above) neutralizes
a reported anxiogenic effect of the un-edited 5-HT2C receptor
(Kennett et al., 1997; Vicente and Zangrossi, 2014). It is consistent
with this conclusion that Vicente and Zangrossi (2014) found
acute injection of the 5-HT2C receptor agonist MK-212 into the
amygdala to have anxiogenic effect, and that chronic treatment
with fluoxetine abolished the anxiety. However, there is also
strong evidence that acute administration of specific agonists
of 5-HT2C receptor are therapeutically effective in depression,
obsessive compulsive disorder and anxiety (Jenck et al., 1998;
Martin et al., 1998; Leysen, 1999; Cryan and Lucki, 2000;
Rosenzweig-Lipson et al., 2007).
The expression of the inhibitory 5-HT1A autoreceptor,
suggested to contribute to the slow manifestation of the
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therapeutic effect of SSRIs (Blier and De Montigny, 1983),
was unaltered after fluoxetine treatment in both neurons and
astrocytes (Peng et al., 2014) and whole brain (Le Poul et al., 2000;
Johnson et al., 2009). This does not mean that its activity could
not have decreased, since a fluoxetine-induced internalization
of the receptor was shown by Descarries and Riad (2012) and
a reduced 5-HT1A receptor expression was found in the raphe
nuclei (Le Poul et al., 2000).
The cell culture finding that SERT is absent in astrocytes
(Kong et al., 2002) was confirmed in freshly isolated astrocytes
from the cerebral hemispheres, excluding raphe nuclei (Peng
et al., 2014). This also applies to neurons, although a minor
presence cannot be excluded (Table 1). Expression of the EGF
receptor, involved in 5-HT2B receptor signaling (Figure 2), is not
altered by chronic fluoxetine treatment in either astrocytes or
neurons (Peng et al., 2014). However mRNA of the equilibrative
nucleoside transporter ENT2 is increased in neurons and even
more in astrocytes after fluoxetine treatment (Table 1), probably
a reflection of the fluoxetine-induced increase in cell generation
(Manev et al., 2003).
The 5-HT2B receptor is downregulated in mice becoming
anhedonic after chronic stress (Li et al., 2012). No similar
downregulation was found of the 5-HT2C receptor, but anhedonia
is only one component of depressive symptomatology, and effects
on the 5-HT2C receptor may mainly influence anxiety.
CONCLUSIONS
The importance of the 5-HT2B receptor in the mechanism of
action of SSRIs has been demonstrated both in vivo (Diaz
et al., 2012) and in cultured astrocytes (Li et al., 2008a). This
paper elucidates its pathway, emphasizes astrocytic-neuronal
interactions in brain function and shows identical effects
of fluoxetine on astrocytic gene expression in our cultured
astrocytes, expressing no SERT, and in drug treated animals. The
latter study also found neuronal effects. The signaling pathway,
studies by other authors and the observed gene effects point
towards the importance in SSRI’s mechanism of action of glucose
and glycogen metabolism, glutamate and GABA turnover and
signaling, cPLA2 and sPLA2 activities, arachidonic acid, cellular
Ca2+ regulation, and alterations in 5-HT2 receptor expression and
editing. Many of the observed effects might be useful targets for
drug development.
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